Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery

Wool Suh,1 Kyung Eun Han,2 and Jae ryong Han1

1Department of Ophthalmology, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea; 2Department of Ophthalmology and Optometry, Ewha Womans University Mok-Dong Hospital, Ewha Womans University School of Medicine, Seoul, Korea

Received: 25 November 2016
Accepted: 7 January 2017

Address for Correspondence:
Jae ryong Han, MD
Department of Ophthalmology, Sacred Heart Hospital, Hallym University College of Medicine, 7 Keunjangdong-gil, Hwaseong 18450, Republic of Korea
E-mail: scarpet@hally.or.kr

Funding: This research was supported by Hallym University Research Fund 2015 (HURF-2015-22).

INTRODUCTION

The most common cause of failure in glaucoma filtering surgery is scarring of the filtering bleb, and the increased amount of collagen in the surgical site suggests that proliferation of fibroblasts with associated production of collagen and glycosaminoglycans is important (1).

Mitomycin C (MMC) has enhanced the surgical success rate of trabeculectomy through inhibition of Tenon capsule fibroblasts with associated production of collagen and glycosaminoglycans. Its use in glaucoma filtration surgery is established by numerous studies. MMC has been shown to improve surgical results in glaucoma filtration surgery and is safe for other ocular tissues simultaneously (2). Therefore, many agents that can modulate wound healing properties; and Ilomastat, an MMP inhibitor. The study demonstrated a significant prolongation of bleb survival compared to the MMC positive control group (9). In another study, the sequential treatment group used the following: Bevacizumab (Avastin), a monoclonal, VEGF antibody; Saratin, a 12 kD polypeptide with anti-inflammatory and anti-thrombotic properties; and Ilomastat, an MMP inhibitor. The study demonstrated a significant prolongation of bleb survival compared to the controls, which was not significantly different from the MMC positive control group (9). In another study, the MMP inhibitor significantly improved surgical outcomes compared with controls and the length of bleb survival was similar to the MMC.

We evaluated the safety of matrix metalloproteinase (MMP) inhibitor in experimental glaucoma filtration surgery in an animal model. Fifteen New Zealand white rabbits underwent an experimental trabeculectomy and were randomly allocated into 3 groups according to the adjuvant agent: no treatment group (n = 5), 0.02% mitomycin C (MMC) soaking group (n = 5), and MMP inhibitor (ilomastat) subconjunctival injection group (n = 5). Slit lamp examination with Seidel testing, pachymetry, and specular microscopy was performed preoperatively and postoperatively. The conjunctiva and ciliary body toxicity were evaluated with scores according to the pathologic grading systems. Electron microscopy was used to examine the structural changes in cornea, conjunctiva, and ciliary body. In the ilomastat-treated group, there was no statistically significant change in central corneal thickness preoperatively and at 28 days postoperatively (P = 0.655). There were also no significant changes in specular microscopy findings over the duration of the study in the ilomastat-treated group. The conjunctival toxicity score was 1 in the control group, 1.5 in the ilomastat-treated group, and 2 in the MMC-treated group. When assessing ciliary body toxicity scores, the ilomastat-treated group score was 0.5 and the MMC-treated group score was 1.5. Transmission electron microscopy did not show structural changes in the cornea and ciliary body whereas the structural changes were noticed in MMC group. A single subconjunctival injection of MMP inhibitor during the experimental trabeculectomy showed a less toxic affect in the rabbit cornea, conjunctiva, and ciliary body compared to MMC.

Keywords: Glaucoma; Filtration; Matrix Metalloproteinase Inhibitor
MATERIALS AND METHODS

Fifteen New Zealand white rabbits aged between 12 and 14 weeks and weighing 2.0 to 2.5 kg were used.

Procedures and examination
Glaucoma filtration surgery was performed only on the right eye similarly to a previous report (11). Animals were randomly divided into 3 groups according to the adjuvant agent used during the surgery: the control group (n = 5), no agent; ilomastat-treated group (n = 5), 0.1 mL of 100 μM ilomastat (Calbiochem-Novabiochem, Nottingham, UK) in a subconjunctival injection; and MMC-treated group (n = 5), a thin cellulose sponge soaked with MMC (0.2 mg/mL). The bleb, conjunctiva, cornea, and anterior chamber were evaluated with slit lamp biomicroscopy and Seidel test preoperatively and at 7 days, 14 days, and 28 days postoperatively. A pachymeter (Ultrasonic pachymeter; Nidek, Aichi, Japan) was used preoperatively and at postoperative 28 days to check the central corneal thickness (CCT). Specular microscopy (Robo-Specular Microscope; Konan Medical Corporation, Nishinomiya, Japan) was performed preoperatively and 28 days postoperatively. At the postoperative 28th day, the rabbits in each group were sacrificed in a CO₂ chamber after isoflurane gas induced anesthesia. The right eye of each rabbit was enucleated to preserve the bleb. Tissues were preserved in 10% formaldehyde, embedded in paraffin, and sequential 3–4 µm sections of the operative wound site were prepared. Hematoxylin and eosin staining was evaluated to check the general cellularity and inflammatory cells. Based on previous reports, the conjunctiva and the ciliary body toxicity were evaluated and scored according to the grading systems by 2 pathologists (12). The scale used for conjunctival changes was: 0 = no histologic change; 1 = minimal histologic change/conjunctiva epithelium preserved, thickening of the conjunctiva; 2 = mild histologic change/conjunctiva epithelium preserved, thickening of the conjunctiva, and mild inflammatory cell infiltration; 3 = moderate histologic change/score 2 with loss of collagen fibril organization; and 4 = severe histologic change: loss of the conjunctival epithelium, total disorganization, and necrosis of the underlying scleral stroma. The scale used for ciliary body changes was: 0 = no histologic change; 1 = minimal histologic change/ciliary epithelium height normal, demonstrating minimal fibroblast proliferation, congestion, and edema, no fibrin; 2 = mild histologic change/ciliary epithelium height decreased, demonstrating moderate fibroblast proliferation with fibrin, moderate congestion, and edema; 3 = moderate histologic change/score 2 with inflammatory cell infiltration; 4 = severe histologic change/desquamation of the ciliary epithelium, total disorganization, and necrosis of the ciliary body. The toxicity of the cornea was also assessed with light modifications.

For transmission electron microscopic observations, the cornea was obtained from the treated eyes immediately postmortem, and fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer for transmission electron microscopic examination. Afterwards, the specimens were postfixed in 1% osmium tetroxide solution, dehydrated and embedded in epoxy resin using the usual procedure. Ultrathin sections of approximately 60–70 nm thickness were made using an Ultracut-E Microtome (Reichert-Jung, Buffalo, NY, USA) and were stained with heavy metals, uranylacetate and lead citrate. Stained sections were assessed and photographed under transmission electron microscopy (TEM; H-7650; Hitachi, Tokyo, Japan).

Statistical analysis
Statistical analyses were conducted using IBM SPSS stastics version 24.0 (IBM Corp., Armonk, NY, USA). The means and standard errors were calculated using descriptive statistics. The Mann-Whitney U test and the Kruskal-Wallis test were used to compare the clinical findings of the groups. Significance was considered at P values < 0.05.

Ethics statement
This study was approved by the Institutional Animal Care and Use Committee of Ewha Medical Center (ESM15-0291). All animal procedures and methods used for securing the animal tissue complied with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and our institutional guidelines.

RESULTS

On postoperative day 7, 14, and 28, fluorescein slit lamp microscopic examination revealed no abnormalities in the bleb conjunctiva such as bleb leakage and blebitis in the ilomastat treated group, whereas one MMC treated eye showed one avascular

| Table 1. Pachymetric result (µm) |
|-----------------------------------|
| **Group**                        | **Before operation** | **Postoperative 28 days** | **P value** |
| Control group                    | 377.0 ± 18.9         | 361.5 ± 10.6              | 0.655       |
| Ilomastat-treated group          | 382.00 ± 22.69       | 384.00 ± 8.28             | 0.655       |
| Mitomycin-treated group          | 372.40 ± 21.17       | 368.33 ± 21.12            | 0.285       |

Values are presented as mean ± SE; SE = standard error.
cystic bleb. In the ilomastat-treated group, cornea problems such as keratitis and corneal ulcer were not noticed via slit lamp examination. Any other adverse events, such as cataract, anterior chamber cell reaction, and endophthalmitis, were not found during the study.

The CCTs in each group are shown in Table 1. CCT was measured before surgery as follows: 377.0 ± 18.9 in controls, 382.00 ± 22.69 in the ilomastat-treated group and 372.40 ± 21.17 in the MMC-treated group. There was no significant difference among the groups \((P = 0.756)\). On postoperative days, CCTs were 361.5 ± 10.6 in the control group, 384.0 ± 8.28 in the ilomastat-treated group, and 368.33 ± 21.12 in the MMC treated group and also showed no statistically significant changes among the 3 groups \((P = 0.253)\). In the ilomastat-treated groups, there were no statistically significant changes in CCT between preoperative and postoperative 28 days \((P = 0.655)\) and the MMC-treated groups also showed no significant change between preoperative and postoperative 28 days \((P = 0.285; \text{Table 1})\).

Specular microscopy findings, such as cell density, coefficient of variation, average cell area, and hexagonality for the 3 groups are shown in Fig. 1 and Table 2. In the ilomastat-treated group, the parameters on preoperative and postoperative 28 days were the following: cell density 2,683 and 2,621, coefficient of variation 40 and 41, average cell area 379 and 398, hexagonality 40 and 28, respectively (Table 2). In the ilomastat-treated group, there was no statistically significant difference in all parameters preoperatively and at postoperative 28 days \((P > 0.05)\). In the MMC-treated group, the coefficient of variation was changed from 19 preoperatively to 31 at postoperative 28 days. The average cell area also decreased from 659 to 374, and hexagonality changed from 67 to 78 in the MMC-treated group. However, when parameters were compared among the 3 groups preoperatively and at postoperative 28 days, there were no statistically significant differences in all parameters \((P > 0.05)\).

When conjunctival toxicity was evaluated, the average score was 1 in the control group, 1.5 in the ilomastat-treated group and 2 in the MMC-treated group. When assessing the ciliary body toxicity score, the ilomastat-treated group was 0.5 and the MMC-treated group was 1.5.

Electron micrographs of corneal structures are shown in Fig. 2. In MMC-treated eyes, variable-sized vacuoles were observed in the cytoplasm of epithelial cells and loss of junctional complexes were observed in basal cells. Multiple vacuoles were also observed in the cytoplasm of keratocyte corneal endothelial cells. In ilomastat-treated eyes, stratified squamous non-keratinized epithelial cells in the tear film were observed and normal long spindle shaped keratocytes were scattered among the lamellae of the stroma. A thick homogenous noncellular Descemet’s membrane lined by a single endothelial cell layer was also noticed. In addition, any other adverse event, such as cataract formation, anterior chamber cell reaction, or endophthalmitis via slit lamp examination, were not found in the ilomastat treated group during the study.

**DISCUSSION**

Glaucoma is a progressive optic neuropathy that may cause blindness if not properly treated. Many glaucoma patients need
glaucoma surgery during the treatment period and glaucoma filtration surgery is usually first attempted to control IOP (13,14). However, the success rate of trabeculectomy is not perfect and many adjunctive antifibrotic agents to modulate the wound healing process of glaucoma filtration surgery have been tried (15). In addition, MMC is one of the most commonly used agents, but it is an antibiotic derived from *Streptomyces caesipitosus* with alkylating properties that exert their most profound cellular toxicity in the late G1 and early S cellular phases (16). MMC can lead to the development of hypotony with a shallow chamber, hypotonic maculopathy, extended choroidal detachment, or a decrease in visual acuity related to progressive cataracts (17). During the many trials to find a more physiologic, alternative agent, a previous study reported that the healing response after surgery could be modulated by inhibiting the effects of MMPs in animal studies. However, a MMP inhibitor is a nonspecific target agent and we did not know the exact mechanism of modulating the wound healing process in filtration blebs. In addition, keratocytes are known to be quiescent in the normal cornea but are readily activated and transformed into myofibroblasts that express a-smooth muscle actin in response to various insults (18). Then myofibroblasts produce ECM, collagen-degrading enzymes, MMPs, and cytokines to compensate for the insults (18). If the MMP inhibitor could influence the cornea as with 5-fluorouracil or MMC, it could further disturb the physiologic compensation process of keratocytes. Therefore, we assessed the safety of the MMP inhibitor in glaucoma filtration surgery, especially the conjunctiva, cornea and ciliary body.

When assessing the corneal endothelium with specular microscopy, in MMC-treated group, the coefficient of variation was

![Fig. 2. Transmission electron microscopic view of cornea.](image-url)
changed from 19 preoperatively to 31 at postoperative 28 days, the average cell area also decreased from 659 to 374, and hexagonality changed from 67 to 78. Electron micrograph of cornea microstructures showed intracytoplasmic multiple vacuoles in epithelial cells, keratocytes, and endothelial cells in the MMC-treated group. Loss of junctional complexes in epithelial layers was observed in the MMC-treated group. In previous human studies, Pastor et al. (6) reported a 4.7% to 20.0% decrease in corneal endothelial cells in 10 patients who underwent trabeculectomies with MMC. In other studies, the mean corneal endothelial cell loss following MMC augmented trabeculectomy was reported to be about 4% to 14% (19). Fukuchi et al. (20) published a report on 2 patients with moderate to severe guttata who underwent trabeculectomy with MMC. It is difficult to compare the exact results because of variation in the study subjects and methods. We used a relatively low dose (0.2 mg/mL) of MMC in a soaking irrigation method that may result in fewer microstructural changes than in previous studies. However, these results showed again that special caution is needed in MMC use regarding corneal microstructures, although there was no definite clinical corneal problem.

There were no adverse corneal problems in the ilomastat-treated group via slit lamp microscopy. In the pachymetric results, there was no statistically significant change in the CCT between preoperative and postoperative 28 day measurements in the ilomastat-treated group ($P = 0.655$). In specular microscopic assessments, there were no significant changes in the endothelial cell density, coefficient of variation, average cell area, and hexagonality between preoperative and postoperative 28 day measurements. Through transmission electron micrographs, in the ilomastat-treated group, cellular integrity was maintained and surface damage or cellular desquamation resulting from toxicity was not observed in the epithelial layers and there was no evident abnormal change in keratocytes and endothelial cells.

In assessing conjunctival toxicity, the conjunctiva epithelium was preserved and minimal histologic changes were found in the ilomastat-treated group compared to the conjunctival changes of the MMC-treated group. Slit lamp microscopic examination revealed no abnormalities in bleb conjunctiva such as bleb leakage and blebitis in the ilomastat treated group, whereas one MMC treated eye showed one avascular cystic bleb. An in vivo study showed MMP inhibition significantly reduced matrix contraction and production without Tenon’s capsule fibroblast toxicity (21). Similar to our study, Martorana et al. (9) also reported that less thinning of tissues and avascularity were noted in the ilomastat-treated group compared to the MMC group.

Regarding the ciliary body toxicity scores, the ilomastat-treated group was 0.5 and the MMC-treated group was 1. Previous studies have shown that episcleral MMC damages the ciliary body, and another study reported that a 5-minute exposure of MMC (0.2 mg/mL, 0.1 mL) in rabbit eyes caused the nonpigmented epithelial cells of the ciliary body to become swollen, and the intracellular abundant mitochondria were swollen and vacuolized (22). Many studies have been conducted to adjust the concentration and application duration of the drug due to the toxic effects of MMC (23). We used MMC (0.2 mg/mL) soaking for 2 minutes in blebs and found mild histologic changes, congestion and edema in the ciliary body. However, the ilomastat-treated group showed less histologic changes compared with the MMC-treated group.

There were some limitations in this study. First, our study was performed in a rabbit model and it is hard to apply our results clinically considering the proliferative capacity of the rabbit endothelium. Second, the number of rabbit eyes used in our study was too low, so there are some limitations in statistical analysis. Therefore, larger scale cases will be needed to confirm the safety of the drug. Third, the authors did not demonstrate drug levels in the ocular tissues. However, the 0.2 mg/mL MMC injection procedure was reported to result in higher conjunctiva, sclera, and aqueous body concentrations and there has been no report on ilomastat intraocular concentrations (24). Forth, we applied a single injection of the MMP inhibitor, so the toxic effect of the drug may have been underestimated whereas previous studies used multiple injections (8-10). Finally, we did not assess the long-term potential toxic effects of the drug.

In conclusion, a single subconjunctival injection of a MMP inhibitor in experimental trabeculectomy showed a less toxic effect on the rabbit corneas, conjunctiva and ciliary bodies compared to MMC. However, the toxicity in human use may be different and more detailed long term studies are needed to confirm the safety of the drug.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conceptualization: Suh W, Han JR. Data curation: Suh W, Han KE. Investigation: Suh W, Han KE, Han JR. Writing - original draft: Suh W, Han KE. Writing - review & editing: Suh W, Han KE, Han JR.

ORCID

Wool Suh http://orcid.org/0000-0002-1953-5684
Kyung Eun Han http://orcid.org/0000-0001-8484-6086
Jae ryong Han http://orcid.org/0000-0003-1663-1440

REFERENCES

1. Filtering surgery. In: Allingham RR, Damji KF, Freedman S, Moroi SE, Shaf-
ranov G, Shields MB, editors. Shields' Textbook of Glaucoma. 5th ed. Philadelphia, PA, Lippincott Williams & Wilkins, 2005, p368-609.
2. Jampel HD. Effect of brief exposure to mitomycin C on viability and proliferation of cultured human Tenon's capsule fibroblasts. *Ophthalmology* 1992; 99: 1471-6.
3. Smith S, D'Amore PA, Dreyer EB. Comparative toxicity of mitomycin C and 5-fluorouracil in vitro. *Am J Ophthalmol* 1994; 118: 332-7.
4. Nyatu RM, Fretton PC, Pels E, Langerhorst CT, Geijssen HC, Grossniklaus HE, Greve EL. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony. *Am J Ophthalmol* 1994; 118: 225-37.
5. Hau S, Barton K. Corneal complications of glaucoma surgery. *Curr Opin Ophthalmol* 2009; 20: 131-6.
6. Pastor SA, Williams R, Hetherington J, Hoskins HD, Goodman D. Corneal endothelial cell loss following trabeculectomy with mitomycin C. *J Glaucoma* 1993; 2: 112-3.
7. Shima I, Katsuda S, Ueda Y, Takahashi N, Sasaki H. Expression of matrix metalloproteinases in wound healing after glaucoma filtration surgery in rabbits. *Ophthal Res* 2007; 39: 315-24.
8. Wong TT, Mead AL, Khaw PT. Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. *Invest Ophthalmol Vis Sci* 2003; 44: 1097-103.
9. Martorana GM, Schaefer JL, Levine MA, Lukowski ZL, Min J, Meyers CA, Schulz GS, Sherwood MB. Sequential therapy with saratin, bevacizumab and ilomastat to prolong bleb function following glaucoma filtration surgery in a rabbit model. *PLoS One* 2015; 10: e0133054.
10. Wong TT, Mead AL, Khaw PT. Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. *Invest Ophthalmol Vis Sci* 2005; 46: 2018-22.
11. Lim DH, Kim TE, Kee C. Evaluation of adenovirus-mediated down-regulation of connective tissue growth factor on postoperative wound healing after experimental glaucoma surgery. *Curr Eye Res* 2016; 41: 951-6.
12. Polak MB, Valamanesh F, Felt O, Torriglia A, Jeanny JC, Bourges JL, Rat P, Thomas-Doyle A, Ben Ezra D, Gurny R, et al. Controlled delivery of 5-fluorouracil using poly (ortho esters) in filtering surgery for glaucoma. *Invest Ophthalmol Vis Sci* 2008; 49: 2993-3003.
13. Weinreb RN, Khaw PT. Primary open-angle glaucoma. *Lancet* 2004; 363: 1711-20.
14. Spaeth G, Walt J, Keener J. Evaluation of quality of life for patients with glaucoma. *Am J Ophthalmol* 2006; 141: S3-14.
15. Suh W, Kee C. The effect of bevacizumab on the outcome of trabeculectomy with 5-fluorouracil. *J Ocul Pharmacol Ther* 2013; 29: 646-51.
16. Dorr RT. New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C. *Semin Oncol* 1988; 15: 32-41.
17. Purikh CH, Edelhauser HF. Ocular surgical pharmacology: corneal endothelial safety and toxicity. *Curr Opin Ophthalmol* 2003; 14: 178-85.
18. Nishida T, Suika S. Basic science: cornea, sclera, ocular adnexa anatomy, physiology and pathophysiologic responses. In: Krachmer JH, Mannis MJ, Holland E, editors. Cornea. 3rd ed. St. Louis, MO, Mosby/Elsevier, 2011, p3-24.
19. Zarei R, Zarei M, Fakhraraie G, Eslami Y, Moghimi S, Mohammadi M, Abdollahi A. Effect of mitomycin-C augmented trabeculectomy on corneal endothelial cells. *J Ophthalmic Vis Res* 2015; 10: 257-62.
20. Fukuchi T, Hayakawa Y, Hara H, Abe H. Corneal endothelial damage after trabeculectomy with mitomycin C in two patients with glaucoma and cornea guttata. *Cornea* 2002; 21: 300-4.
21. Daniels JT, Cambrey AD, Oclesten NL, Garrett Q, Tarnuzzer RW, Schultz GS, Khaw PT. Matrix metalloproteinase inhibition modulates fibroblast-mediated matrix contraction and collagen production in vitro. *Invest Ophthalmol Vis Sci* 2003; 44: 1104-10.
22. Xia X, Jiang Y, Huang P, Wu Z, Zeng Q, Wen J. Cytotoxic effect of mitomycin C on the nonpigmented epithelium of ciliary body in rabbit eyes. *Zhongguo Yan Ke Za Zhi* 1998; 34: 190-3.
23. Getinkaya A, Akman A, Take G, Bilezikci B, Akova YA. Ciliary body toxicity of subconjunctival suramin compared with mitomycin-C in the rabbit eye: determining the toxic concentration. *Ophthalmic Res* 2009; 41: 91-7.
24. Kawase K, Matsushita H, Yamamoto T, Kitazawa Y. Mitomycin concentration in rabbit and human ocular tissues after topical administration. *Ophthalmology* 1992; 99: 203-7.